Objectives To assess consistency in the format and content, and overlap of subject and timing, of medication safety letters issued by regulatory health authorities to healthcare providers in Canada, the USA and the UK. Design A cross-sectional study comparing medication safety letters issued for the purpose of alerting healthcare providers to newly identified medication problems associated with medications already on the market. Setting Online databases operated by Health Canada, the US Food and Drug Administration and the UK Medicines and Healthcare products Regulatory Agency were searched to select medication safety letters issued between 1 January 2010 and 31 December 2014. Format, content and timing of each medication safety letter were...
Paramount attention is often afforded to pharmacotherapies being brought to market. The anticipation...
Aims: Regulatory risk communications are important to ensure medication safety, but their impact is ...
Introduction. Adverse drug events (ADEs) caused by medication errors occur regularly in hospitals. R...
Background Information about the safety of medicines often emerges after approval. Medicines’ regul...
The European Medicines Agency (EMA) and national regulators share the responsibility to communicate ...
The safety information on drug labels of a company marketing the same drugs in different countries i...
In the wake of the withdrawal of the nonsteroidal anti-inflammatory drug rofecoxib, regulators world...
OBJECTIVE: To compare consistency of adverse drug reaction (ADR) data in publicly available product ...
Medication-related adverse events are a major cause of disability and death,1 and one of the most co...
OBJECTIVE: To evaluate the association between regulatory drug safety advisories and changes in drug...
Cornelius VR, Liu K, Peacock J, Sauzet O. Variation in adverse drug reactions listed in product info...
Inaccessibility of drug reports When new drugs are launched,physicians must have access to the rando...
Introduction When serious medication errors (ME) are identified, communication to the field may be n...
Monitoring adverse drug reactions (ADRs) through pharmacovigilance is vital to health consumer safet...
Paramount attention is often afforded to pharmacotherapies being brought to market. The anticipation...
Aims: Regulatory risk communications are important to ensure medication safety, but their impact is ...
Introduction. Adverse drug events (ADEs) caused by medication errors occur regularly in hospitals. R...
Background Information about the safety of medicines often emerges after approval. Medicines’ regul...
The European Medicines Agency (EMA) and national regulators share the responsibility to communicate ...
The safety information on drug labels of a company marketing the same drugs in different countries i...
In the wake of the withdrawal of the nonsteroidal anti-inflammatory drug rofecoxib, regulators world...
OBJECTIVE: To compare consistency of adverse drug reaction (ADR) data in publicly available product ...
Medication-related adverse events are a major cause of disability and death,1 and one of the most co...
OBJECTIVE: To evaluate the association between regulatory drug safety advisories and changes in drug...
Cornelius VR, Liu K, Peacock J, Sauzet O. Variation in adverse drug reactions listed in product info...
Inaccessibility of drug reports When new drugs are launched,physicians must have access to the rando...
Introduction When serious medication errors (ME) are identified, communication to the field may be n...
Monitoring adverse drug reactions (ADRs) through pharmacovigilance is vital to health consumer safet...
Paramount attention is often afforded to pharmacotherapies being brought to market. The anticipation...
Aims: Regulatory risk communications are important to ensure medication safety, but their impact is ...
Introduction. Adverse drug events (ADEs) caused by medication errors occur regularly in hospitals. R...